Pharmaceuticals

Respiratory Biologics Market Overview 2026–2030 With Insights On Industry Developments

May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Respiratory Biologics Market Grow Between 2026 And 2030?

The dimensions of the respiratory biologics market have seen swift growth recently. This market is anticipated to expand from $7.41 billion in 2025 to $8.61 billion in 2026, achieving a compound annual growth rate (CAGR) of 16.3%. Historically, this growth has been driven by factors such as limitations of conventional inhalers, rising severe asthma cases, biologic therapy approvals, improved immunology research, and specialty clinic expansion.

The respiratory biologics market size is anticipated to undergo significant growth over the next few years. It is projected to expand to $15.66 billion by 2030, achieving a compound annual growth rate (CAGR) of 16.1%. This expansion during the forecast period can be attributed to the rise of precision respiratory medicine, the broadening of biologics pipelines, increasing healthcare spending, improved reimbursement policies, and persistent unmet needs in severe respiratory diseases. Prominent trends for the forecast period include the increasing adoption of targeted biologic therapies, the expansion of treatments for severe asthma, a surge in biomarker-based patient selection, the growing use of injectable respiratory drugs, and a shift towards long-acting biologic agents.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23497&type=smp

What Major Factors Are Driving The Respiratory Biologics Market Forward?

The escalating air pollution is anticipated to drive the future expansion of the respiratory biologics market. Air pollution is defined as the existence of harmful substances such as gases, particulate matter, and biological molecules in the Earth’s atmosphere, which can have adverse effects on human health and the environment. This pollution is intensifying due to increasing industrialization and urbanization, leading to higher emissions of contaminants from factories, vehicles, and construction activities. Respiratory biologics play a crucial role in mitigating the health impacts of air pollution by providing targeted treatments that reduce inflammation and improve lung function in individuals exposed to airborne pollutants. For example, in January 2025, the Environmental Protection Agency, a US-based government agency, reported that the United States released over 66 million tons of pollutants into the atmosphere in 2023. Thus, the growing air pollution is significantly fueling the growth of the respiratory biologics market.

How Is Segmentation Applied In The Respiratory Biologics Market Segment Analysis?

The respiratory biologics market covered in this report is segmented –

1) By Disease Indication: Asthma, Chronic Rhinosinasitis, Hypereosinophilic Syndrome

2) By Route Of Administration: Intravenous, Subcutaneous

3) By Sales Channel: Hospitals, Specialty Clinics, Retail Pharmacies, Mail Order Pharmacies

Subsegments:

1) By Asthma: Severe Eosinophilic Asthma, Allergic Asthma, Non-Allergic Asthma

2) By Chronic Rhinosinasitis: Chronic Rhinosinusitis: Chronic Rhinosinusitis with Nasal Polyps, Chronic Rhinosinusitis without Nasal Polyps

3) By Hypereosinophilic Syndrome (HES): Idiopathic HES, Lymphocytic Variant HES, Myeloproliferative HES

What Trends Are Affecting The Direction Of The Respiratory Biologics Market?

Major companies in the respiratory biologics market are concentrating on developing advanced biologic therapies, such as targeted immune therapies for chronic respiratory diseases. These efforts aim to provide precise treatments that reduce inflammation and improve lung function. Targeted immune therapies for chronic respiratory diseases function by helping to regulate the body’s immune system, thereby lessening swelling and breathing difficulties in long-term lung conditions. For instance, in September 2024, Sanofi S.A., a France-based pharmaceutical company, announced the US Food and Drug Administration (FDA) approved Dupixent (dupilumab) as an add-on maintenance therapy for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) who exhibit an eosinophilic phenotype. This approval marked a significant event, as Dupixent became the first biologic medicine sanctioned in the US for treating this specific patient group with COPD.

Who Are The Companies Participating In The Respiratory Biologics Market Environment?

Major companies operating in the respiratory biologics market are Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Amgen Inc., Swedish Orphan Biovitrum AB, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Pfizer Inc., Merck & Co. Inc., Bristol Myers Squibb Company, Johnson & Johnson, Boehringer Ingelheim International GmbH, Biogen Inc., Vertex Pharmaceuticals Incorporated, Glenmark Pharmaceuticals Ltd., Kiniksa Pharmaceuticals Ltd., Pieris Pharmaceuticals Inc.

Get The Full Respiratory Biologics Market Report:

https://www.thebusinessresearchcompany.com/report/respiratory-biologics-global-market-report

Where Is The Respiratory Biologics Market Primarily Concentrated By Region?

North America was the largest region in the respiratory biologics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Respiratory Biologics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/respiratory-biologics-global-market-report

Browse Through More Reports Similar to the Global Respiratory Biologics Market 2026, By The Business Research Company

Respiratory Devices And Equipment Therapeutic And Diagnostic Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-therapeutic-and-diagnostic-global-market-report

Respiratory Devices And Equipment Therapeutic Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-therapeutic-global-market-report

Respiratory Disease Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-disease-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795